Pre-cessation nicotine replacement therapy: pragmatic randomized trial

被引:43
作者
Bullen, Chris [1 ]
Howe, Colin [1 ]
Lin, Ruey-Bin [1 ]
Grigg, Michele [2 ]
Laugesen, Murray [3 ]
McRobbie, Hayden [4 ]
Glover, Marewa [5 ]
Walker, Natalie [1 ]
Wallace-Bell, Mark [6 ]
Whittaker, Robyn [1 ]
Rodgers, Anthony [7 ]
机构
[1] Univ Auckland, Sch Populat Hlth, Clin Trials Res Unit, Auckland 1, New Zealand
[2] Quit Grp, Wellington, New Zealand
[3] Hlth New Zealand, Lyttelton, New Zealand
[4] Univ London, Barts & London Sch Med & Dent, Wolfson Inst Prevent Med, London, England
[5] Univ Auckland, Sch Populat Hlth, Ctr Tobacco Control Res Social & Community Hlth, Auckland 1, New Zealand
[6] Univ Canterbury, Hlth Sci Ctr, Christchurch 1, New Zealand
[7] George Inst Int Hlth, Sydney, NSW, Australia
关键词
Cessation; clinical trial; nicotine replacement therapy; pragmatic; pre-cessation; quit; randomized; smoking; SMOKING-CESSATION; PRECESSATION TREATMENT; ABSTINENCE RATES; PATCH; DEPENDENCE; SYMPTOMS; QUITLINE; GUM;
D O I
10.1111/j.1360-0443.2010.02989.x
中图分类号
R194 [卫生标准、卫生检查、医药管理];
学科分类号
摘要
Aims To determine the effectiveness of 2 weeks' pre-cessation nicotine patches and/or gum on smoking abstinence at 6 months. Design Pragmatic randomized controlled trial. Setting New Zealand. Participants Eleven hundred adult, dependent smokers who called the New Zealand Quitline between March 2006 and May 2007 for support to stop smoking were randomized to 2 weeks of nicotine patches and/or gum prior to their target quit day followed by usual care (8 weeks of patches and/or gum plus support calls from a Quitline adviser), or to usual care alone. Measurements The primary outcome was self-reported 7-day point prevalence smoking abstinence 6 months after quit day. Secondary outcomes included continuous abstinence, cotinine-verified abstinence, daily cigarette consumption, withdrawal symptoms and adverse events. Findings Six months after quit day 125 (22.7%) participants in the pre-cessation group and 116 (21.0%) in the control group reported 7-day point prevalence abstinence (relative risk 1.08 95% CI: 0.86, 1.35, P = 0.4, risk difference 1.7%, 95% CI: -3.2%, 6.6%). However, when pooled in a meta-analysis with other pre-cessation trials a moderate benefit of about a one-quarter increase in cessation rates was evident. There was no difference in adverse events between groups. Conclusions In this, the largest pre-cessation NRT trial to date, using NRT 2 weeks before the target quit day was safe and well tolerated but offered no benefit over usual care. However, in conjunction with previous pre-cessation trials there appears to be a moderate benefit, but not as large as that seen in most smaller trials.
引用
收藏
页码:1474 / 1483
页数:10
相关论文
共 32 条
[1]  
[Anonymous], NZ MED J
[2]  
[Anonymous], ANN M SOC RES NIC TO
[3]  
[Anonymous], NICOTINE TOB RES, DOI DOI 10.1080/1462220021000032753
[4]   Recruitment Into a Cessation Trial Via the New Zealand Quitline: Many Benefits, Few Limitations [J].
Bullen, Chris ;
Howe, Colin ;
Grigg, Michele ;
Phillips, Frances ;
Silcock, Rose ;
Glover, Marewa ;
McRobbie, Hayden ;
Whittaker, Robyn .
JOURNAL OF SMOKING CESSATION, 2008, 3 (01) :30-34
[5]   Diagnostic accuracy of NicAlert cotinine test strips in saliva for verifying smoking status [J].
Cooke, Fiona ;
Bullen, Chris ;
Whittaker, Robyn ;
McRobbie, Hayden ;
Chen, Mei-Hua ;
Walker, Natalie .
NICOTINE & TOBACCO RESEARCH, 2008, 10 (04) :607-612
[6]   Nicotine replacement therapy for long-term smoking cessation: a meta-analysis [J].
Etter, Jean-Francois ;
Stapleton, John A. .
TOBACCO CONTROL, 2006, 15 (04) :280-285
[7]   Nicotine Gum Treatment Before Smoking Cessation A Randomized Trial [J].
Etter, Jean-Francois ;
Huguelet, Philippe ;
Perneger, Thomas V. ;
Cornuz, Jacques .
ARCHIVES OF INTERNAL MEDICINE, 2009, 169 (11) :1028-1034
[8]  
Fiore MC., 2008, TREATING TOBACCO USE
[9]   Subsidised nicotine replacement therapy [J].
Grigg, M ;
Glasgow, H .
TOBACCO CONTROL, 2003, 12 (02) :238-239
[10]  
HEATHERTON TF, 1991, BRIT J ADDICT, V86, P1119